SoylentNews is people
SoylentNews
One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.
[...] The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.
[...] Ars reached out to Goldman Sachs, which confirmed the content of the report but declined to comment.
(Score: 0) by Anonymous Coward on Monday April 16 2018, @06:03AM (1 child)
After all if you have a serious genetic problem that might be passed to your children, with 7+ billion people already on this planet what makes your disease ridden fetus so worth keeping? Just because it has your crappy genes?
If you want a baby without those faulty genes I can donate some sperm and someone else can provide the eggs. It'll be 99% like you minus your serious diseases, even if it's not even the same race or color, that's what those anti-racism scientists claim right? So you can achieve mostly the same thing without gene modification if it's all about being rational.
(Score: 2) by The Mighty Buzzard on Monday April 16 2018, @10:27AM
It'd be worth proposing that just to watch the butthurt that exploded when the left realized sickle cell anemia was one of those instances. I do love me a good troll.
My rights don't end where your fear begins.